TG Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.: Annual Revenue Growth Compared

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market position. Over the past decade, Amphastar Pharmaceuticals, Inc. and TG Therapeutics, Inc. have showcased contrasting trajectories in their annual revenue growth.

Amphastar Pharmaceuticals has demonstrated a steady upward trend, with revenue increasing by approximately 206% from 2014 to 2023. This growth reflects the company's robust product pipeline and strategic market expansions. In contrast, TG Therapeutics experienced a dramatic surge in 2023, with revenue skyrocketing to over $233 million, marking a significant milestone after years of modest earnings. This leap can be attributed to successful product launches and increased market penetration.

While Amphastar's consistent growth underscores its stable market presence, TG Therapeutics' recent breakthrough highlights its potential for rapid expansion. These trends offer valuable insights into the evolving landscape of the biotech industry.